PL424468A1 - Sposób określenia ryzyka raków u kobiet w zależności od stężeń arsenu i/lub kadmu i/lub cynku we krwi - Google Patents

Sposób określenia ryzyka raków u kobiet w zależności od stężeń arsenu i/lub kadmu i/lub cynku we krwi

Info

Publication number
PL424468A1
PL424468A1 PL424468A PL42446818A PL424468A1 PL 424468 A1 PL424468 A1 PL 424468A1 PL 424468 A PL424468 A PL 424468A PL 42446818 A PL42446818 A PL 42446818A PL 424468 A1 PL424468 A1 PL 424468A1
Authority
PL
Poland
Prior art keywords
risk
cancer
cadmium
blood
women
Prior art date
Application number
PL424468A
Other languages
English (en)
Inventor
Jan LUBIŃSKI
Anna Jakubowska
Wojciech MARCINIAK
Magdalena MUSZYŃSKA
Róża Derkacz
Katarzyna Kaczmarek
Tomasz Huzarski
Jacek Gronwald
Cezary Cybulski
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL424468A priority Critical patent/PL424468A1/pl
Publication of PL424468A1 publication Critical patent/PL424468A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób ustalenia ryzyka raka u kobiet, polegający na tym, że w pobranej od pacjentki próbce biologicznej, zwłaszcza krwi lub surowicy badaną obecność konstytucyjnej mutacji BRCA1/2 skorelowanej z podwyższonym ryzykiem zachorowania na raka a także stężenia Cd, Zn, As. Ustalono, że istnieje korelacja między stężeniem arsenu kadmu i cynku we krwi pełnej a ryzykiem raków u kobiet nie będących nosicielkami żadnej z mutacji założycielskich w genie BRCA1/2 typowych dla populacji Polskiej zarówno przed jak i po 60 roku życia oraz w zależności od palenia tytoniu.
PL424468A 2018-02-02 2018-02-02 Sposób określenia ryzyka raków u kobiet w zależności od stężeń arsenu i/lub kadmu i/lub cynku we krwi PL424468A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL424468A PL424468A1 (pl) 2018-02-02 2018-02-02 Sposób określenia ryzyka raków u kobiet w zależności od stężeń arsenu i/lub kadmu i/lub cynku we krwi

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL424468A PL424468A1 (pl) 2018-02-02 2018-02-02 Sposób określenia ryzyka raków u kobiet w zależności od stężeń arsenu i/lub kadmu i/lub cynku we krwi

Publications (1)

Publication Number Publication Date
PL424468A1 true PL424468A1 (pl) 2019-08-12

Family

ID=67549954

Family Applications (1)

Application Number Title Priority Date Filing Date
PL424468A PL424468A1 (pl) 2018-02-02 2018-02-02 Sposób określenia ryzyka raków u kobiet w zależności od stężeń arsenu i/lub kadmu i/lub cynku we krwi

Country Status (1)

Country Link
PL (1) PL424468A1 (pl)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HSIEN WEN KUO, SERUM AND TISSUE TRACE ELEMENTS IN PATIENTS WITH BREAST CANCER IN TAIWAN, 2002 *
MONA MOHAMED K. EL-DEEB, THE ROLE OF SERUM TRACE ELEMENTS AND OXIDATIVE STRESS IN EGYPTIAN BREAST CANCER PATIENTS, 2016 *
NALAN DEMIR, ASSOCIATION OF CADMIUM BUT NOT ARSENIC LEVELS IN LUNG CANCER TUMOR TISSUE WITH SMOKING, HISTOPATHOLOGICAL TYPE AND STAGE, 2014 *
STEPHANIE A. NAVARRO SILVERA, TRACE ELEMENTS AND CANCER RISK: A REVIEW OF THE EPIDEMIOLOGIC EVIDENCE, 2007 *

Similar Documents

Publication Publication Date Title
Kim et al. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut–liver axis
Allin et al. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population
Ishii et al. Gender, obesity and repeated elevation of C-reactive protein: data from the CARDIA cohort
Fan et al. Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation
Jaworska et al. A low selenium level is associated with lung and laryngeal cancers
Martinez-Lopez et al. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality
Almeida et al. NKT-like (CD3+ CD56+) cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
Ma et al. Inherited thrombophilia and portal vein thrombosis in cirrhosis: a systematic review and meta‐analysis
Banias et al. Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition
Lee et al. High expression of phospho-H2AX predicts a poor prognosis in colorectal cancer
Riva et al. Human S100A9 protein is stabilized by inflammatory stimuli via the formation of proteolytically-resistant homodimers
Barosi et al. Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease
Maguire et al. Analyses of ionizing radiation effects in vitro in peripheral blood lymphocytes with Raman spectroscopy
Iida et al. Prognostic significance of IL-17 mRNA expression in peritoneal lavage in gastric cancer patients who underwent curative resection
PL425603A1 (pl) Sposób określenia ryzyka raków u kobiet będących nosicielkami mutacji w genie BRCA1 i BRCA2 w zależności od stężeń we krwi arsenu, kadmu, cynku i/lub selenu
Schurman et al. Age-related disease association of endogenous γ-H2AX foci in mononuclear cells derived from leukapheresis
Barilà et al. Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation
Silva et al. PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters
Arnold et al. Investigating cervical, oesophageal and colon cancer risk and survival among migrants in The Netherlands
Hermans et al. Risk factors for cancer of unknown primary: a literature review
Brant et al. Screening for prostate cancer by using random-effects models
PL425602A1 (pl) Sposób określenia ryzyka raków u kobiet nie będących nosicielkami mutacji w genie BRCA1 i BRCA2 w zależności od stężeń we krwi arsenu, kadmu, cynku i/lub selenu
PL424468A1 (pl) Sposób określenia ryzyka raków u kobiet w zależności od stężeń arsenu i/lub kadmu i/lub cynku we krwi
Hemminki et al. Familial risks in in situ cancers from the Family-Cancer Database.
Murray et al. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer